Summary
- Current Price
- As of today, HALO price is $67.44, up +0.48% on
- Current Price All-Time High
- HALO price is currently -17.98% below its historical high of $82.22 set on
- Market Cap
- HALO current market cap is $8B, up +21.80% over the past 365 days
- PE Ratio
- HALO current PE ratio is 24.25
- Revenue
- HALO current annual revenue is $1.40B, up +37.55% year-over-year
- Next Earnings
- The next earnings release for HALO is on
Profile
| Metric | Value |
|---|---|
| Full Name | Halozyme Therapeutics, Inc. |
| Ticker | NASDAQ: HALO |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | halozyme.com |
| Employees | 350 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $67.44 | |
| Price, 1D Change | +0.48% | |
| $8B | ||
| - | ||
| 24.25 | ||
| 0.61 | ||
| $1B | ||
| Revenue, 1Y Change | +37.55% | |
| $2.56 | ||
| EPS, 1Y Change | -25.47% |
Chart
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | HTI | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| $2.56 | ||
| EPS Estimate | N/A | $8.11 |
| EPS Est. Change | N/A | +217.03% |
| $1.40B | ||
| Revenue Estimate | N/A | $1.78B |
| Revenue Est. Change | N/A | +27.18% |
| Current Price | $67.44 | |
| Price Target | - | $90.00 |
| Price Tgt. Change | - | +33.45% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $4.13 | $3.43 | -16.87% | |
| $6.55 | $2.56 | -60.98% | |
| $8.11 | N/A | +217.03% | |
| $9.84 | N/A | +284.56% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $1.00B | $1.02B | +1.21% | |
| $1.39B | $1.40B | +0.21% | |
| $1.78B | N/A | +27.18% | |
| $2.00B | N/A | +42.96% |
🔒 Log In To Unlock Full Data
Performance
Technicals
| Metric | Date | Value |
|---|---|---|
| Current Price | $67.44 | |
| $68.96 | ||
| SMA 200 vs Price | +2.25% | |
| $65.58 | ||
| SMA 50 vs Price | -2.76% | |
| 0.61 | ||
| $2.65 | ||
| 52.52 | ||
| 47.19% | ||
| 29.74% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| $1.40B | ||
| $2.56 | ||
| $1.09B | ||
| 78.13% | ||
| $816.29M | ||
| 58.45% | ||
| $316.89M | ||
| 22.69% | ||
| $904.34M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| 44.60 | ||
| 4.66 | ||
| 3.66 | ||
| - | ||
| 6 | ||
| 3.62 |
Valuations
| Metric | Date | Value |
|---|---|---|
| 24.25 | ||
| 5.30 | ||
| 36.42 | ||
| 10.23 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| $48.81M | ||
| $142.82M | ||
| $2.71B | ||
| $825.21M | ||
| $2.67B | ||
| $177.09M | ||
| $2.18B | ||
| $11.28M | ||
| $20.90M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $1.08B | ||
| $274.88M | ||
| $305.44M | ||
| $0.00 | ||
| $88.05M | ||
| $0.00 | ||
| $149.99M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| $651.56M | ||
| -$545.81M | ||
| -$85.17M | ||
| $6.97M | ||
| $644.59M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Morgan Stanley | → | |
| HC Wainwright & Co. | → | |
| Wells Fargo | → | |
| Benchmark | → | |
| TD Cowen | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| Goldman Sachs | → | |
| Citizens | → | |
| JP Morgan | → |
Analyst sentiment
Institutional ownership
Screeners with HALO
FAQ
What is the ticker symbol for Halozyme Therapeutics, Inc.?
The ticker symbol for Halozyme Therapeutics, Inc. is NASDAQ:HALO
Does Halozyme Therapeutics, Inc. pay dividends?
No, Halozyme Therapeutics, Inc. does not pay dividends
What sector is Halozyme Therapeutics, Inc. in?
Halozyme Therapeutics, Inc. is in the Healthcare sector
What industry is Halozyme Therapeutics, Inc. in?
Halozyme Therapeutics, Inc. is in the Biotechnology industry
What country is Halozyme Therapeutics, Inc. based in?
Halozyme Therapeutics, Inc. is headquartered in United States
When did Halozyme Therapeutics, Inc. go public?
Halozyme Therapeutics, Inc. initial public offering (IPO) was on March 16, 2004
Is Halozyme Therapeutics, Inc. in the S&P 500?
No, Halozyme Therapeutics, Inc. is not included in the S&P 500 index
Is Halozyme Therapeutics, Inc. in the NASDAQ 100?
No, Halozyme Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Halozyme Therapeutics, Inc. in the Dow Jones?
No, Halozyme Therapeutics, Inc. is not included in the Dow Jones index
When was Halozyme Therapeutics, Inc. last earnings report?
Halozyme Therapeutics, Inc.'s most recent earnings report was on May 11, 2026
When does Halozyme Therapeutics, Inc. report earnings?
The next expected earnings date for Halozyme Therapeutics, Inc. is August 4, 2026
Data Sources & References
- HALO Official Website halozyme.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1159036/000115903626000024/0001159036-26-000024-index.htm
- HALO Profile on Yahoo Finance finance.yahoo.com/quote/HALO
- HALO Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/halo